Leerink Partnrs Boosts Earnings Estimates for Tourmaline Bio

Tourmaline Bio, Inc. (NASDAQ:TRML) – Stock analysts at Leerink Partnrs boosted their FY2025 earnings per share (EPS) estimates for shares of Tourmaline Bio in a research report issued on Wednesday, December 11th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings of ($3.56) per share for the year, up from their previous forecast of ($4.01). The consensus estimate for Tourmaline Bio’s current full-year earnings is ($3.08) per share. Leerink Partnrs also issued estimates for Tourmaline Bio’s FY2026 earnings at ($4.58) EPS, FY2027 earnings at ($6.32) EPS and FY2028 earnings at ($7.22) EPS.

Other equities analysts also recently issued reports about the stock. BMO Capital Markets started coverage on shares of Tourmaline Bio in a report on Friday, December 6th. They set an “outperform” rating and a $50.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 price target on shares of Tourmaline Bio in a research note on Wednesday. HC Wainwright reiterated a “buy” rating and set a $49.00 price objective on shares of Tourmaline Bio in a research note on Wednesday. Finally, Guggenheim restated a “buy” rating on shares of Tourmaline Bio in a research report on Wednesday. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $54.00.

Tourmaline Bio Stock Performance

Tourmaline Bio stock opened at $21.81 on Friday. The stock has a market capitalization of $559.21 million, a P/E ratio of -7.73 and a beta of 2.32. The company’s fifty day moving average price is $26.02 and its 200 day moving average price is $19.86. Tourmaline Bio has a 1 year low of $12.12 and a 1 year high of $48.31.

Tourmaline Bio (NASDAQ:TRML) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.78) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.06.

Institutional Trading of Tourmaline Bio

Hedge funds have recently bought and sold shares of the business. Quest Partners LLC increased its stake in shares of Tourmaline Bio by 134.0% in the 2nd quarter. Quest Partners LLC now owns 3,822 shares of the company’s stock worth $49,000 after acquiring an additional 2,189 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Tourmaline Bio by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 4,932 shares of the company’s stock valued at $127,000 after purchasing an additional 1,920 shares during the period. The Manufacturers Life Insurance Company acquired a new stake in Tourmaline Bio during the third quarter worth about $226,000. California State Teachers Retirement System purchased a new position in Tourmaline Bio during the first quarter worth about $334,000. Finally, MetLife Investment Management LLC acquired a new position in Tourmaline Bio in the 3rd quarter valued at about $357,000. Institutional investors and hedge funds own 91.89% of the company’s stock.

About Tourmaline Bio

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.